Biopharmaceutical company, atai Life Sciences (Nasdaq: ATAI) joined the PRISM MarketView Emerging Psychedelics Index this week. The company was founded in response to the significant…
March 06, 2024
IceCure Medical Ltd. (Nasdaq: ICCM) has announced new data from a preliminary, independent breast cancer studyshowing median tumor reduction of 100% at six and 12…
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) has reached the ‘Last Patient, Last Visit’ milestone in its Phase 2b/3 Trial of NRX-101 in suicidal treatment resistant bipolar…
High-definition diagnostics company, Quanterix Corporation (Nasdaq: QTRX), has been granted Breakthrough Device designation by the FDA for its Simoa® phospho-Tau 217 (p-Tau 217) blood test…
Clinical stage biotechnology company, Quoin Pharmaceuticals (Nasdaq: QNRX) has received FDA clearance to recruit subjects aged 14 years and older into its two ongoing clinical…
NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO) has received Institutional Review Board (IRB) approval to proceed with its Phase 1 clinical trial of DA-1726 for the treatment…
Lexaria Bioscience (Nasdaq: LEXX) continues to advance its CBD-based candidate for hypertension with the clearance of its investigational new drug (IND) application by the FDA…
February 29, 2024
Adial Pharmaceuticals Lands Pivotal US Patent for Lead Product for Addiction Disorder Treatment; Shares Soar 229%
Adial Pharmaceuticals Inc (NASDAQ:ADIL) revealed that the United States Patent and Trademark Office issued patent number 11,905,562 on February 20, 2024. This new patent encompasses…
February 29, 2024
Incannex’s Psilocybin Targets Anxiety with Positive Topline Results
Leading cannabinoid and psychedelic medicine biotechnology company, Incannex Healthcare (Nasdaq: IXHL), has achieved positive topline results in its Phase 2 clinical trial of psilocybin in…
February 28, 2024
MindMed Closes Out 2023 with Positive Phase 2b Results for Generalized Anxiety Treatment
Mind Medicine (MindMed) Inc. (Nasdaq: MNMD) has announced its financial results for the year ended December 31, 2023, closing out a “highly productive” year with…
February 26, 2024
Arcturus Granted Orphan Designation by European Commission in Win for Cystic Fibrosis Patients
Arcturus Therapeutics (Nasdaq: ARCT) has been granted orphan medicinal product designation by the European Commission (EC) for ARCT-032 in the treatment of Cystic Fibrosis (CF)….
February 22, 2024
NeuroSense Reports Additional Positive Data from ALS Trial
Neurodegenerative disease company, NeuroSense Therapeutics (Nasdaq: NRSN) has reported additional positive data from its six-month double-blind Phase 2b PARADIGM trial of PrimeC for the treatment…